Sixth Wave Innovations (SIXW / AHUH)

  • Neues Interview mit CEO Gluckman

    External Content
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    SIXW.CN hat grad einen ziemlich guten News Flow, der im 2. Semester anhalten oder sich gar verstärken dürfte. Der Kurs hat sich jedenfalls gefangen und positiv entwickelt in den letzten Tagen.

  • Die Technologie scheint immer spannend zu sein, ebenso wie ihre Expertise und Entwicklungen. Aber ich finde es immer noch schwierig, kurzfristige Ergebnisse zu sehen, es gibt immer noch eine gewisse Undurchsichtigkeit. Insbesondere für Gold (auch wenn wir wissen, dass dies in diesem Sektor nicht über Nacht geschehen wird) und Viren. Der Zeitplan für Affinity ist klarer, aber es gibt keine Gewissheit, dass er eingehalten wird, und der Partner ist nicht sehr zuverlässig (nicht einmal bei Google erwähnt).

  • News…y-achieves-110000028.html

    Das sind m.E. sehr bedeutende / vielversprechende Neuigkeiten. Mir gefällt dabei u.a. folgende Passage:

    "The Company is quickly moving through a program of development and scale-up milestones toward a wide range of AMIPs virus rapid detection devices. The spectrum of prospective products will include SIXW's SmartMask™ offerings (see SIXW Press Release dated May 15, 2020), in addition to smart-clothing, PPE applications, airborne sensors, breathalyzers, ELISA-based technologies, cartridge/lateral flow designs, and others."

    Komischerweise/leider reagiert der Kurs kaum auf diese Nachricht.

  • News - ohne nennenswerte Kursreaktion

    Press Release
    December 13, 2021

    Sixth Wave Readies to Commercialize Technology for Fast, Accurate, and Inexpensive Covid-19 Tests

    Halifax, Nova Scotia – (December 13, 2021) – Building on its revolutionary approach to detecting the virus that causes Covid-19, Sixth Wave Innovations Inc. (CSE:SIXW) (OTCQB:SIXWF) (FSE:AHUH) (“Sixth Wave” or the “Company”) is working to commercialize its technology, advancing the prospect of widely available Covid tests that can rapidly, accurately, and inexpensively detect the presence of the virus and its mutations.

    Sixth Wave has used the fully owned intellectual property of its molecular imprinted polymer technology to develop its patent-pending Accelerated Molecular Imprinted Polymer (“AMIPs™”) platform that provides virus detection that can be deployed in a host of devices and new environments not serviced by current technologies.

    Sixth Wave has been approached by commercial partners seeking to use the AMIPs™ technology in both personal and environmental devices. For personal testing, AMIPs™ could be deployed in simple kits that provide a fast, accurate diagnosis from saliva instead of a nasal swab, or from handheld breathalyzers that could be used multiple times by the same user for easier, less expensive, less wasteful testing.

    Other potential partners have expressed interest in the quicker-to-market opportunity to use Sixth Wave technology to monitor indoor air and water for the virus. Deploying AMIPs™ in sensors or other devices would provide real-time alerts to the presence of the Covid-causing virus in enclosed spaces, from homes, offices and school classrooms to entertainment venues, airplanes, and aboard cruise ships.

    With Covid infections continuing to rise around the world, finding ways to test people and environments affordably, easily, and reliably has become an essential tool for mitigating the economic and social consequences of the disease.

    Vastly Improved Personal Testing

    Sixth Wave’s technology overcomes problems that riddle current methods to test for Covid-19 that require using biological materials (antibodies) to detect the virus. PCR tests are expensive, generally require unpleasant nasal swabs, and rely on laboratory analysis to return results. Rapid antigen tests are faster but significantly less accurate, diminishing in effectiveness as the virus mutates.

    Sixth Wave brings a synthetic solution to those shortcomings. Working on live SARS-CoV-2 viruses alongside researchers at the University of Alberta’s world-renowned Li Ka Shing Institute of Virology, the Company has demonstrated that AMIPs™ captures the presence of the Covid-causing virus with similar sensitivity to conventional antigen tests.

    Notably, AMIPs™ has continually proven its ability to detect variants of the SARS-CoV-2 virus that causes Covid-19. Similar testing will begin on the highly transmissible Omicron variant as soon as virus samples become available.

    The AMIPs™ laboratory findings have been validated by the Li Ka Shing Institute of Virology, and the Company has filed three patents related to the AMIPs™ technology.

    Testing Enclosed Environments for Covid

    Working with researchers from York University, Sixth Wave has undertaken the development of environmental applications for AMIPs™ that, unlike diagnostic tests, do not require regulatory approval to be deployed. The York researchers have validated the electrochemical and fluorescent detection methods of the technology.

    This development stream offers a quick-to-market path to generate revenue. Sixth Wave has already been approached by potential commercial partners seeking to deploy AMIPs™ in sensors to monitor enclosed environments for the presence of the virus. From sports stadiums to theatres, office buildings to schools, and hospitals, there is a massive need for real-time testing to alert people to a heightened risk of disease.

    Working with a device manufacturing partner, the Company could have an AMIPs™-based product ready for field testing in six months under the right conditions.

    Next Steps

    Sixth Wave has taken a methodical approach to demonstrate the clinical progress of AMIPs™ with the goal of creating marketable products with applications in personal health care and environmental monitoring.

    Following that strategic path, the Company will continue to work with the Li Ka Shing Institute researchers using saliva samples and live viruses to validate its findings that detection matches or exceeds antigen tests. It expects to complete that work in Q2 of 2022 and submit results and AMIPS to a third party for validation.

    The Company is now engaged with four potential partners to commercialize the AMIPs™ platform. Several test kit designs will be pursued either under the SIXW AMIPs™ brand or under license. They include:

    • Incorporating AMIPs™ into test kits that are like current antigen tests but have significant cost savings, and greater ease-of-use (the Company has already engaged with a potential manufacturing partner on this approach).

    • Continuing work in electronic detection for a simple, handheld, breathalyzer with a replaceable cartridge containing the AMIPs™ sensor or for testing that could incorporate wireless or Bluetooth capability to share data. The breathalyzer could be used multiple times by the same user to further reduce costs.

    • Continuing development of a SmartMask™ concept using AMIPs™ that has potential for almost ubiquitous applications.

    • Sixth Wave will accelerate work with potential manufacturing partners to advance the environmental monitoring applications of the AMIPs™ technology. The Company is ready to produce sensors for pathogen testing and integration into air and water handling systems to monitor for viral pathogens. The Company and York University have filed additional grant applications to continue supplementing this work.
    The Company will also begin more comprehensive selectivity testing against other respiratory viruses and bacteria. That testing will start in January 2022.

    “We are very pleased with our progress to date.” Notes Dr. Jonathan Gluckman, President and CEO of Sixth Wave. “The accelerated timeline for this accomplishment is a testament to the underlying technology platform we have developed over a number of years. We are confident that our advances toward commercialization are foundational and will benefit the use the AMIPS platform in delivering a diversity of future virus detection products.”

    The Company is not making any express or implied claims that its current AMIPs™ product can eliminate, cure, contain, or detect, at a commercial level, COVID-19 (or SARS-2 coronavirus) at this time. No agreements have been executed with potential commercial partners at this time.

  • Geht da noch was oder bald Totalverlust?

    Tja, wenn der Kurs einer Aktie kontinuierlich abschmiert, wird's halt ruhig im Forum...

    Ich ärgere mich darüber, dass ich bei Sixth Wave Innovations für meine Verhältnisse viel zu stark investiert bin. Sitze hier auf einem erheblichen Buchverlust und frage mich, ob es hier noch Grund zur Hoffnung gibt.

    Wie seht ihr das?

  • Wie blöd kann man sein?

    lupin: geht mir genau so. Kann nicht fassen, dass ich hier mehrere Tausend Franken investiert habe. Völlig unvernünftig. Ich hoffe, es wird mir eine Lehre sein. Inzwischen habe ich beinahe einen Totalverlust, da lohnt sich ein Verkauf fast nicht mehr. Ich bleibe investiert bis zum bitteren Ende (oder einer überraschenden Wende zum Guten...)

  • nachtfalter hat am 23.01.2021 00:32 geschrieben:

    Möchte jetzt nicht besserwisserisch rüberkommen, tut mir leid für alle welche hier Verluste erleiden.